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Abstract
In the past few decades, chronic hepatitis B (CHB) 
has evolved from a disease that was untreatable and 
progressive, to one that can be easily controlled with 
antiviral therapy. However, patients with severe liver 
disease still remain difficult to treat despite the avail-
ability of highly potent nucleos(t)ide analogs. These 
include those with underlying cirrhosis, severe flares 
of CHB, hepatocellular carcinoma (HCC), and for those 
undergoing liver transplantation. For those with estab-
lished cirrhosis, antiviral therapy should be considered 
for all, as unpredictable flares can still occur, which can 
be fatal for those with advanced chronic liver disease. 
However, even with effective viral suppression, the 
development of HCC can still occur. For patients with 
severe flares of CHB, although the use of antiviral can 
improve long term outcomes, a significant proportion 
may still die without liver transplantation. The short 
term prognosis of these patients is dependent on both 
the severity of flare and underlying pre-existing liver 
disease. In patients with decompensated cirrhosis, 
liver failure secondary to severe flares, or those with 
HCC, liver transplantation may be curative. After liver 
transplantation, long term antiviral therapy is required 
to prevent graft loss from recurrent hepatitis B infec-
tion. The use of hepatitis B immune globulin (HBIG) in 
combination with an oral antiviral agent has been the 
mainstay of post-transplant antiviral regimen for over a 
decade. With newer and more potent antiviral agents 
such as tenofovir and entecavir, use of these agents 
along with HBIG have demonstrated to be effective in 
preventing significant recurrence in the long term.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: This review discusses the treatment of chron-
ic hepatitis B in patients with underlying severe liver 
disease, including cirrhosis, acute on chronic liver fail-
ure, hepatocellular carcinoma, and those undergoing 
liver transplantation. Despite the availability of highly 
potent antiviral drugs, these patients are often diffi-
cult to manage. The use of currently available antiviral 
agents is discussed along with its efficacy in these pa-
tients with severe hepatitis B liver disease.
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INTRODUCTION
With an estimated 400 million people worldwide infected 
with the hepatitis B virus (HBV), chronic hepatitis B 
(CHB) continues to be a major global health problem. 
Up to 40% of  patients infected with CHB may develop 
liver complications, including cirrhosis, liver decom-
pensation, and hepatocellular carcinoma (HCC)[1]. In a 
recent study of  6689 CHB patients, HBV was the cause 
of  death in over 40%, and the rate was similar between 
non-Asians and Asia-Pacific Islander origin[2]. Not until 
the recent decade, CHB was largely a progressive and un-
treatable disease. The major milestone in CHB manage-
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ment was the approval of  the first nucleoside/nucleotide 
analogue (NA), lamivudine (LAM) in 1998. However, 
LAM was associated with high rates of  resistance[3]. Since 
then, four other NAs have been approved for the treat-
ment of  CHB, namely adefovir (ADV), entecavir (ETV), 
telbivudine, and tenofovir (TDF). All NAs are effective 
in achieving the short term goals of  HBV DNA suppres-
sion and normalization of  liver parenchymal enzymes[4-11]. 
The key difference between the NAs pertain to their 
varying barriers to resistance[12]. Through the effects of  
viral suppression, long-term treatment with NAs can 
reduce and prevent the development of  cirrhosis and 
reduce the development of  HCC[13-17]. However, a signifi-
cant proportion of  HBV carriers remain untreated for 
various reasons. As CHB is largely asymptomatic, HBV 
carriage is unlikely to be apparent unless it is screened. 
Once diagnosed, treatment may not be instituted because 
of  ineligibility according to current treatment guidelines, 
cost, compliance to follow-up, and patient’s own decision. 
It is therefore not surprising that a significant proportion 
of  HBV carriers can present for the first time with ad-
vanced liver disease.
MANAGEMENT OF CIRRHOSIS
In patients with advanced fibrosis and established cirrho-
sis, long term therapy with NAs can lead to regression 
of  fibrosis and even cirrhotic changes[18-22]. However, in 
advanced stages of  cirrhosis, when the liver is already 
contracted with gross lobular architectural distortions and 
portal hypertension, the changes are likely to be irrevers-
ible. Although antiviral therapy should ideally have been 
started prior to the onset of  progressive liver fibrosis, 
there are major reasons for treating patients with estab-
lished cirrhosis. The goals of  treatment for this popula-
tion are to prevent further liver injury and progressive 
liver damage leading to decompensation, to improve liver 
function, and to decrease the risk of  HCC development 
and ultimately, to reduce mortality.
Ideally, all CHB patients with cirrhosis and detectable 
viral load should be considered for treatment. However, 
there are differences in the criteria for starting antiviral 
therapy for HBV cirrhosis between the major regional 
treatment guidelines. The European Association for the 
Study of  the Liver guidelines recommend that treatment 
should be started using a drug with low resistance pro-
file irrespective of  the level of  alanine aminotransferase 
(ALT) as this may be normal in advanced liver disease[23]. 
The American Association for the Study of  Liver Dis-
eases (AASLD) guidelines suggest that treatment for 
compensated patients should only be started when ALT 
> × 2 upper limit of  normal, or if  the HBV DNA level 
is elevated (> 2000 IU/mL) with elevated ALT[24]. For 
patients with decompensated cirrhosis, treatment should 
be promptly initiated with a NA that can rapidly suppress 
viral load with a low risk of  drug resistance. The Asia 
Pacific Association for the Study of  the Liver (APASL) 
guidelines recommend treatment for those with HBV 
DNA levels ≥ 2000 IU/mL with compensated cirrho-
sis[25]. However, spontaneous flares of  hepatitis can occur 
at any time, and in patients with cirrhosis (even if  com-
pensated), these episodes may lead to decompensation, 
increasing chance of  death or the need for liver trans-
plantation (LT). Therefore, all HBV cirrhotic patients 
who remain hepatitis B surface antigen (HBsAg) positive 
should be considered for antiviral therapy.
The duration of  therapy for patients with cirrhosis 
should be long-term. For compensated cirrhosis, the 
AASLD guidelines recommend that treatment can be 
stopped in hepatitis B e antigen (HBeAg)-positive pa-
tients if  they undergo HBeAg seroconversion together 
with at least 6 mo of  consolidation therapy, or in the 
event of  HBsAg seroconversion for HBeAg-negative 
patients[24]. However, the risk of  virological rebound in 
patients with treatment-induced HBeAg seroconver-
sion after cessation of  antiviral therapy has been shown 
to be significantly high[26]. As virological rebound and 
subsequent flare after discontinuing treatment may re-
sult in decompensation in cirrhotic patients, it would 
be prudent to consider long-term maintenance antiviral 
therapy. For decompensated patients, life-long treatment 
is recommended.
The long term benefits of  oral antiviral therapy in 
cirrhotic CHB patients was established in a multicenter 
randomized placebo-controlled trial of  651 patients us-
ing LAM, showing significant reduction in overall disease 
progression, lower rate of  Child-Pugh score increase, and 
a reduction in the development of  HCC[13]. Subsequent 
non-placebo trials have demonstrated the efficacy of  
newer NAs in decompensated liver disease. A random-
ized study comparing ETV and ADV demonstrated 
superior viral suppression with ETV, with similar im-
provements in Child-Pugh scores[27]. A randomized study 
comparing TDF (n = 45), TDF + emtricitabine (n = 45), 
and ETV (n = 22) showed similar efficacy in HBV DNA 
suppression, and improvement in Child-Pugh and MELD 
scores[28]. In fact, an earlier study using LAM showed a 
biphasic survival pattern, with a high mortality rate within 
the first 6 mo due to liver failure in patients with decom-
pensated cirrhosis[29]. Factors associated with early mor-
tality included bilirubin, creatinine, and HBV DNA levels. 
For those surviving beyond 6 mo, the long term survival 
was excellent (88% at 3 years). The importance of  HBV 
DNA suppression in decompensated cirrhotic patients 
was highlighted in a randomized placebo-controlled trial 
using TDF in 27 patients[30]. Those patients treated with 
TDF had significant reduction in HBV DNA levels with 
improvements in Child-Pugh and MELD scores, and 
reduction in mortality. A greater than 2 log reduction in 
HBV DNA levels at week 2 was found to be an indepen-
dent predictor of  survival.
It is likely that the short term survival is independent 
of  the type of  antiviral therapy, and non-head to head 
comparison studies have shown similar 1-year survival 
rates of  84%-93% between the five currently approved 
NAs in decompensated CHB cirrhosis[29,31,32]. As previ-
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ously mentioned, virtually all patients with cirrhosis who 
are commenced on antiviral therapy will require life-long 
treatment. Therefore, NAs with a high barrier to resis-
tance should be used to minimize the risk of  virological 
breakthrough and subsequent flares, as this can often 
lead to disastrous consequences in patients with estab-
lished cirrhosis[33-38]. A recent meta-analysis comparing 
ETV and LAM showed similar reduction in mortality, 
with better virological response and lower rate of  resis-
tance observed in those treated with ETV[39].
In patients with severe liver disease, there should be 
heightened vigilance to ensure that any adverse effects 
from medication use are minimized. There have been 
cases of  severe lactic acidosis occurring with the use of  
ETV in patients with impaired liver function[40]. These 
patients all had higher MELD scores of  > 18 with im-
paired creatinine clearance. Therefore, patients with re-
nal impairment should have their antiviral dose adjusted 
accordingly. In the randomized trials of  ETV in decom-
pensated cirrhosis, no lactic acidosis was reported[27,28].
ACUTE FLARE OF CHB
Acute flare of  CHB can occur in both treatment-naïve 
patients and those already on antiviral therapy. In the for-
mer setting, loss of  immunotolerance in HBeAg-positive 
patients may result in acute flares. For those who are 
HBeAg-negative, ongoing viral replication can still oc-
cur, leading also to recurrent flares. For treated patients, 
acute flares can occur with cessation of  therapy or non-
compliance, and also with the development of  drug 
resistant mutations. In severe cases, acute flares can lead 
to acute on chronic liver failure (AOCLF). The APASL 
consensus has defined AOCLF as an acute hepatic insult 
manifesting as jaundice and coagulopathy, complicated 
within 4 wk by ascites and/or encephalopathy in patients 
with existing chronic liver disease[41]. The development 
of  AOCLF depends on 2 key factors, the severity of  the 
acute insult and the degree of  underlying chronic liver 
disease. Liver failure can occur with a moderate flare 
with underlying cirrhosis, or with a severe flare in non-
cirrhotic patients.
As discussed previously, the biphasic pattern of  survival 
means that a significant proportion will succumb within the 
first few mo of  presentation even with the commence-
ment of  antiviral therapy. The use of  molecular adsor-
bent recirculating system (MARS) can decrease plasma 
concentration of  bilirubin, creatinine, and ammonia in 
AOCLF. Initial small randomized trials of  patients with 
AOCLF suggested that using albumin dialysis may im-
prove survival[42-44]. However, in a recent multicenter trial 
of  189 AOCLF patients randomized to receive MARS (n 
= 95) vs standard (n = 94) therapy, there was no differ-
ence in the 28 d transplant-free survival (60% vs 59.2% 
respectively, P = 0.88) and in the 90-d transplant-free 
survival (44.7% vs 43.7% respectively, P = 0.97)[45]. Thus 
although MARS therapy is safe in this group of  patients, 
there does not appear to be any survival benefit.
Therefore, for those patients not responding to an-
tiviral therapy, LT remains the only curative option. For 
those with evidence of  liver decompensation, early refer-
ral to a LT center is recommended. There is currently 
no consensus on whom and when to transplant, and 
the most widely adopted criteria is the King’s criteria for 
acute liver failure. However, many of  these patients have 
underlying chronic liver disease and may not fulfil the cri-
teria for acute liver failure. In addition, patients with AO-
CLF often evolved into a chronic state, without fulfilling 
the King’s criteria, but remain decompensated without 
transplantation. There are studies showing that MELD 
score on presentation could be used to predict mortal-
ity from AOCLF. For patients with MELD score greater 
than 30, the short-term mortality can be as high as 92% 
even when NAs are given[46,47]. These patients should be 
urgently considered for LT. For those with intermedi-
ate MELD score e.g., 20-30, the short-term mortality is 
around 44%-50%. Monitoring other prognostic param-
eters is therefore required and LT may also be required. 
These parameters include prothrombin time, INR, cre-
atinine, sodium, the presence of  hepatic encephalopathy, 
the presence of  cirrhosis, hepatorenal syndrome, HBeAg 
status, and albumin[48-51]. In the absence of  the definite 
criteria for AOCLF, clinical judgment is often made on 
factors such as the presence of  hepatic encephalopathy, 
degree of  liver dysfunction including the level of  jaundice 
and coagulopathy, the presence of  multiorgan involve-
ment, and the use of  imaging to determine the presence 
of  underlying cirrhosis, portal hypertension and dynamic 
changes in liver size with serial scanning.
The outcome after LT for AOCLF is excellent, and 
is similar to those achieved by LT for other liver condi-
tions. In a study of  50 patients with acute flare of  CHB 
and 99 cirrhotic patients with acute decompensation, the 
5-year survival rate was 93.2% and 90.5% respectively[52].
HEPATOCELLULAR CARCINOMA
It is well known that HBV replication is an important 
contributing factor for the development of  HCC[53]. An-
tiviral therapy remains the cornerstone in reducing the 
incidence in HCC[54]. Studies using LAM demonstrate 
a reduction in HCC development in both cirrhotic and 
non-cirrhotic patients, although the benefit is diminished 
by the development of  drug resistance[3,13,55]. Failure to 
remain in virological remission is a risk factor for HCC[56]. 
A case control study showed a lower cumulative 5-year 
HCC incidence in patients treated with ETV compared to 
the control group (3.7% vs 13.7% respectively, P < 0.001), 
with a lower risk of  HCC in the ETV group (HR = 0.37, 
95%CI: 0.15-0.91, P = 0.30)[16]. An analysis of  2671 CHB 
patients, antiviral therapy was associated with a lower 
risk of  HCC compared with non-treated patients (ad-
justed HR = 0.39, 95%CI: 0.27-0.56, P < 0.001)[57]. Sev-
eral meta-analyses/systematic reviews have also shown 
the benefits of  antiviral therapy in reducing the rate of  
HCC development[58-61]. A recent systematic review and 
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meta-analysis however was less clear on the benefits of  
antiviral therapy in preventing HCC and mortality[62]. Un-
fortunately, antiviral therapy will not completely remove 
the risk of  HCC, especially for those with established cir-
rhosis where the liver is already prone to carcinogenesis 
even without viral replication[56]. Therefore, close follow-
up and stringent surveillance for the development of  
HCC is essential for all cirrhotic patients.
Once HCC develops, treatment for HBV will depend 
on the stage of  disease and the treatment undertaken. 
Ideally, all patients should be on antiviral therapy as the 
majority will have underlying cirrhosis. Even for non-
cirrhotic patients, the fact that HCC has developed shows 
that the virus itself  has an important role in hepatocar-
cinogenesis. For non-surgical patients, a high viral load 
prior to chemotherapy results in higher rates of  severe 
hepatitis during chemotherapy[63]. The APASL guidelines 
recommend that antiviral treatment should be com-
menced in all HCC patients with HBV DNA > 2000 IU/
mL before and/or after curative therapy, and treatment 
should be started preemptively for all patients undergoing 
transarterial chemo-embolization (TACE)[25]. Longer sur-
vival has been shown in patients receiving TACE with the 
additional of  antiviral therapy[64]. For those with advance 
stage HCC where survival is limited, resistance becomes 
less of  an issue, and a more cost-effective approach may 
be recommended[65].
For the overwhelming majority of  patients with HCC, 
surgical removal of  the tumor by resection or LT is the 
only curative option; the latter will be discussed in a 
subsequent section. Antiviral therapy is important for 
patients undergoing resection as the hepatic reserves 
will be limited and compromised in the post-operative 
period. Therefore, flares of  hepatitis may lead to decom-
pensation for untreated patients[66]. Surgery and anesthe-
sia may also impart a state of  immunosuppression in the 
early post-operative period, thereby increasing the risk 
of  HBV reactivation[67]. A high pre-operative viral load 
has been associated with worse overall and recurrence-
free survivals after curative resection[68]. There is also 
the potential increased risk of  recurrent HCC due to the 
process of  necrosis and regeneration of  remaining hepa-
tocytes, which may induce DNA mutations and instabil-
ity. Up-regulation of  adhesion molecules on cells lining 
sinusoids may increase the risk of  distant metastasis[69].
Viral load and hepatic inflammatory activity have 
been associated with late recurrences after HCC resec-
tion[70]. A cohort of  72 resected patients with HBV-relat-
ed HCC showed that the absence of  antiviral treatment 
was a risk in tumor recurrence[71]. An HBV DNA of  > 
2000 IU/mL at the time of  resection was a significant 
risk factor (RR = 22.3, 95%CI: 3.3-150.5, P = 0.001). In a 
nationwide cohort study from Taiwan of  4051 untreated 
vs 518 NA-treated CHB patients with resected HCC, 
even though there was a higher rate of  cirrhosis in the 
latter (38.7% vs 48.6% respectively, P < 0.001), the risk 
of  HCC recurrence was lower in the NA-treated patients 
(43.6% vs 20.5% respectively, P < 0.001)[72]. NA use was 
independently associated with a significantly lower HCC 
recurrence risk (HR = 0.67, 95%CI: 0.55-0.81, P < 0.001).
Therefore, antiviral therapy plays an important role 
in preventing the development of  HCC, but also in the 
recurrence of  HCC after curative resection. A meta-
analysis also demonstrated the beneficial effects of  anti-
viral therapy with regards to HCC recurrence (OR = 0.59, 
95%CI: 0.35-0.97, P = 0.04), and liver-related mortality 
(OR = 0.13, 95%CI: 0.02-0.69, P = 0.02)[73]. Another 
recent meta-analyses including 20 studies demonstrated 
that the presence of  high viral load significantly in-
creased overall HCC recurrence risk after curative ther-
apy, whereas antiviral therapy had potential beneficial 
effects in preventing recurrence[74].
LIVER TRANSPLANTATION
Indications for LT in CHB include severe flares, chronic 
decompensation, and the development of  HCC. The 
goals of  therapy for these patients have been discussed 
in detail for patients with acute flares, decompensated 
cirrhosis, and also for patients with HCC[75]. There is 
also evidence to suggest that antiviral therapy before LT 
may prevent HBV recurrence after LT by reducing the 
level of  viremia to extremely low levels[76-78]. After LT, 
the primary goal of  antiviral therapy is to prevent HBV 
recurrence and to prevent graft loss. Prior to the avail-
ability of  effective HBV prophylaxis in the 1980s, LT for 
CHB was a relative contraindication. High rates of  graft 
re-infection leading to severe flares and loss of  graft oc-
curred in the absence of  antiviral therapy. The use of  
hepatitis B immune globulin (HBIG) after LT was the 
first major milestone in the prevention of  post-trans-
plant HBV recurrence. HBIG monotherapy reduced 
HBV recurrence by a rate of  approximately 70%[79]. As 
it is a type of  passive immunization, the effects are im-
mediate and transient, resulting in the need for frequent 
antibody titer monitoring and parental injection. The 
second milestone was the approval of  LAM for the 
treatment of  CHB. Although LAM monotherapy is ef-
fective in preventing 60%-95% of  HBV recurrence, a 
major disadvantage is the high rate of  drug resistance[80]. 
By combining HBIG with LAM, over 95% of  HBV re-
currence can be prevented. This combination has been 
the mainstay of  therapy for most LT centers worldwide 
for the past few decades. The cost of  HBIG therapy can 
be reduced through the use of  lower doses which have 
shown to be equally efficacious[81].
With the availability of  highly potent NAs with low 
drug resistance rates, recent studies have shown that 
an HBIG-free regimen can be adopted. An early small-
scaled study demonstrated that HBIG can be safely 
withdrawn with the addition of  ADV together with LAM 
without an increase risk in virological relapse[82]. A recent 
study also demonstrated no HBV recurrence at 96 wk for 
patients treated with emtricitabine + TDF + HBIG, with 
cessation of  HBIG after 6 mo post LT[83]. A completely 
HBIG-free regimen in a cohort of  CHB patients using 
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ETV monotherapy, has been reported, showing no epi-
sodes of  HBV flares or graft loss secondary to recurrent 
HBV infection[84]. The combination of  LAM + ADV 
without HBIG has also been shown to be effective[85]. A 
recent large long-term cohort study of  362 CHB post-LT 
patients receiving only NAs without HBIG showed that 
at year 8 after LT, 98% had undetectable HBV DNA. 
Moreover, the survival was excellent at 83% at 8 years, 
with no mortality related to HBV recurrence[86]. This 
clearly shows that an HBIG-free regimen is safe and ef-
fective, and increasing studies have also demonstrated the 
efficacy of  this therapeutic approach[87-93].
However, HBIG remains part of  the antiviral pro-
phylaxis in many transplant centers. It has to be said 
that the use of  HBIG is likely to result in a higher rate 
of  HBsAg negativity due to the fact that the passive 
anti-HBs antibodies will bind with HBsAg, leading to a 
further reduction in detection rate when compared with 
HBIG-free protocols. However, this does not signify 
eradication of  HBV as cessation of  prophylaxis is likely 
to result in reactivation. Therefore, life-long antiviral 
therapy is currently the standard of  care after LT for 
CHB.
CONCLUSION
In patients with CHB, complications of  liver disease 
can occur in around 40% of  patients, including cirrho-
sis and HCC. The use of  interferon-based therapy is 
largely contra-indicated for those with severe liver disease; 
therefore treatment is restricted to the use of  NAs. After 
curative resection, adjuvant interferon therapy also fails 
to demonstrate any reduction in recurrence of  HCC af-
ter curative resection[94]. Although there are slight varia-
tions between the different major regional treatment 
guidelines, general recommendations can be made with 
the use of  the current available NAs in the treatment 
of  patients with cirrhosis, AOCLF, HCC, and after LT. 
The use of  drugs with high antiviral potency and high 
barrier to resistance is recommended (ETV or TDF), 
to minimize the development of  resistance, virologi-
cal breakthrough and biochemical flare. Earlier drugs 
with low antiviral potency or low barrier to resistance, 
such as LAM or ADV, should not be used. The duration 
of  treatment is life-long for the overwhelming major-
ity, with cessation of  therapy perhaps only possible for 
those with HBsAg seroconversion. Ongoing surveillance 
for HCC is an essential component of  management 
for cirrhotic patients. In patients with HCC, antiviral 
therapy is recommended to preserve liver function in 
the non-tumor liver, especially for those undergoing liver 
resection and loco-regional ablative therapy. For those 
with AOCLF and those with decompensated cirrhosis, 
early consideration for transplantation is recommended 
if  available. Although antiviral therapy is effective for 
AOCLF, a significant proportion will still succumb. Life-
long prophylaxis is currently the standard of  care for 
patients after transplant. With the newer NAs, a regimen 
without the use of  HBIG has been shown to be effec-
tive with excellent long-term outcome.
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